Breaking Finance News

AstraZeneca (NYSE:AZN) has been upgraded from Mkt Perform to Outperform in a report by Bernstein today.

Bernstein has upgraded AstraZeneca (NYSE:AZN) from Mkt Perform to Outperform in a report released on 9/22/2017.

Yesterday AstraZeneca (NYSE:AZN) traded 3.08% higher at $32.81. The company’s 50-day moving average is $30.33 and its 200-day moving average is $31.81. The last closing price is up 6.31% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 3,869,846 shares of the stock traded hands, down from an average trading volume of 5,212,640

See Chart Below

AstraZeneca (NYSE:AZN)

AstraZeneca has a 52 week low of $25.55 and a 52 week high of $35.60 with a P/E ratio of 22.18 The company’s market cap is currently $0.

In addition to Bernstein reporting its stock price target, a total of 4 brokers have issued a research note on the company. The average stock price target is $35.41 with 1 broker rating the stock a strong buy, 0 brokers rating the stock a buy, 3 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About AstraZeneca (NYSE:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.